Post-marketing Surveillance (Special Use-results Surveillance) on Treatment With Alhemo

Inclusion Criteria

• •Signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).
• •The decision to initiate treatment with commercially available Alhemo has been made by the participant/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the participant in this study.
• •Male or female, age above or equal to 12 years at the time of signing informed consent.
• •Diagnosis with Haemophilia A (HA) or Haemophilia B (HB).
• •Participant who has never been exposed to concizumab or who starts treatment with concizumab within the past 12 weeks at registration.